Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/FDFDFDF2.svg?ark=w1%2F20260526%2FFDFDFDF2&value=id)](https://nobleid.org/work/w1/20260526/FDFDFDF2)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors